Nektar and Puretech make strange bedfellows
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
Puretech’s cautionary tale about pivotal study read-across
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
FDA decision time looms for Gelesis
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
Gamma-delta follows financing with consolidation
A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.
Why Immatics could soon become the next listed cell therapy player
Immunocore and Adaptimmune could shortly have a publicly listed rival.
